The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLV.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Haro-Estarriol M, Sabater-Talaverano G, Rodríguez-Jerez F, Obrador-Lagares A, Genís-Batlle D, Sendra-Salillas S

[Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline].

Archivos de bronconeumologia 2009 Feb;45;100-2 — 2009 Feb — 100-2

Muñoz-Morente A, Garcia-Trujillo L, Soto-Hurtado EJ, González-Benítez MA

[Recurrent nerve paralysis and pleural effusion due to cabergoline].

Revista de neurologia 2008 Mar 16-31;46;382-3 — 2008 Mar 16-31 — 382-3

Guptha SH, Promnitz AD

Pleural effusion and thickening due to cabergoline use in a patient with Parkinson's disease.

European journal of internal medicine 2005 Apr;16;129-131 — 2005 Apr — 129-131